first look concert new neuro asset reit buy rais pt
think new asset land sweet spot concert
yesterday call compani discuss newli
unveil compound deuter form d-serin
treatment schizophrenia view asset land sweet
spot compani core compet leverag valid
deuter platform in-hous expertis furthermor
risk diversif point view balanc pipelin portfolio
clinic valid compound absenc potenti ip
baggag note due ip disput
rate around degre uncertainti around
commerci upsid given gener natur d-serin
think major risk profil predominantli clinic futur
indic expans would encumb ip issu base
exist literatur believ mechanist support d-serin
solid discuss opinion success develop
boil safeti profil need valid
character clinic whether higher dose d-serin
presum wider therapeut window inde
translat better clinic outcom addit note
compani expect report result mg mg cohort
phase studi treatment alopecia areata
year end ahead readout base optimist outlook
rais price target previou
continu next page
definit distribut analyst rate analyst certif disclosur pleas refer page report
like strategi compani histor identifi scientif sound clinic
valid compound efficaci safeti properti enhanc deuter process think
deuter d-serin nmda receptor co-agonist solid mechanist clinic rational go
clinic posit symptom schizophrenia hallucin delus thought associ
hyperdopaminergia bodi evid support nmda receptor hypofunct hypothesi underli
neg symptom apathi emot withdraw cognit impair decreas level nmda receptor found
schizophrenia patient ketaimin nmda receptor antagonist elicit posit neg symptom
note d-serin well character studi pre-clin clinic although efficaci d-serin
schizophrenia patient somewhat inconsist studi studi open-label studi adjunct d-serin
high dose shown signific improv vs baselin posit
neg symptom patient schizophrenia measur posit neg
syndrom scale panss kantrowitz et al schizophrenia research pilot double-blind placebo-
control studi d-serin individu high risk schizophrenia kantrowitz et al lancet psychiatri
may also demonstr signific improv neg symptom vs placebo
take-away clear clinic valid d-serin reduc biolog clinic risk give
us comfort assess potenti util addit current standard-of-car drug like risperidon olanzapin
effect address neg symptom presum due bias activ toward serotonin dopamin
receptor moreov competitor like acadia buy take differ approach target receptor
view alreadi address variou degre exist antipsychot drug also highlight fact
popul schizophrenia individu schizophrenia neg symptom therefor
think may open fit adjunct treatment regimen complementari mechan
boil safeti dose believ ultim success deuter compound function either
ad efficaci safeti perhap even case think boil improv renal
safeti profil suggest preclin model whether higher dose d-serin perhap even higher
day might translat better clinic outcom higher score thu far appear significantli decreas renal
toxic compar d-serin rat measur creatinin blood urea nitrogen level certainli view result
encourag take conserv stanc see preclinical/clin data note preclin studi
clear evid nephrotox associ d-serin open-label studi d-serin cite
kg/day dose one subject show proteinuria without glycosuria final week treatment signific chang
creatinin resolv follow d-serin discontinu patient mg/kg phase discontinu
studi asymptomat transamin safeti issu observ dose suggest
us renal toxic may signific concern d-serin certain dose threshold reach
presum valu higher dose without renal toxic may partial depend optim dose yet
determin end think key question regard dose high go human subject without
incur untoward toxic whether go beyond current dose limit propos d-serin would inde provid
markedli enhanc benefit note evid support dose-depend respons kantrowitz
paper cite unclear whether optim dose alreadi achiev perhap
lie beyond addit caution worsen effect cognit excess nmda activ
associ higher dose
number compani record revenu whole year primarili driven asset purchas
agreement neutral net loss net
incom full year share decemb compani cash cash
equival invest
valuat risk price target aa ad agit
cash base discount cash flow analysi use discount rate growth rate line
expect discount growth paramet development-stag biotechnolog compani risk invest thesi
target price includ failur clinic studi failur secur regulatori approv smaller anticip
commerci opportun due market size competit price
mm except per share valu
revenu
revenu
revenu
net incom tax
provis incom tax
tax incom
net incom attribut common stockholders-dilut
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc cnce- us
rate price target histori inc acad- us
rate price target histori inc vrtx- us
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl march
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein li wang watsek certifi view express report accur reflect person
view subject secur issuer discuss part compens directli
indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur concert
pharmaceut inc inc inc includ without limit option
right warrant futur long short posit
februari neither firm affili benefici class common equiti secur
inc inc
neither research analyst firm materi conflict interest research analyst know
reason know time public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc
invest bank servic within twelv month seek compens
compani mention report invest bank servic within three month follow public research
firm make market inc inc
inc date research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit part report may reproduc form without express permiss
